In this way, in a preclinical trial in mice with malignancies, it was discovered that the tumor size and progression were dramatically reduced after the combination of anti-CTLA-4 monoclonal antibodies with HPV E6/E7-specific vaccinations. Here, CTLA4 is linked to cancer.